24 Jul 2014 --- In the first half of 2014, Lonza’s Specialty Ingredients and Pharma&Biotech segments both delivered a sound performance despite currency headwinds and are fully on track to deliver the growth targets. Compared with the same period in 2013, sales growth of 3.2% to CHF 1.8 billion and CORE EBIT growth of 13.1% to CHF 241 million are coming from the implementation of growth projects and from restructuring activities.
